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doi:10.1Objective: Intra-aortic balloon pumps are traditionally inserted through the femoral artery, limiting the patient’s
mobility. We used alternate approaches of intra-aortic balloon pump insertion to provide temporary and mini-
mally invasive support for patients with decompensating, end-stage heart failure. The present study describes the
outcomes with closed-chest, transthoracic intra-aortic balloon pumps by way of the subclavian artery.
Methods:During a 3-year period, 20 patients underwent subclavian artery–intra-aortic balloon pump in the set-
ting of end-stage heart failure. The balloon was inserted through a polytetrafluoroethylene graft sutured to the
right subclavian artery in 19 patients (95%) and to the left subclavian artery in 1 patient (5%). The goal of sup-
port was to bridge to transplantation in 17 patients (85%) and bridge to recovery in 3 patients (15%). The pri-
mary outcome measure was death during subclavian artery–intra-aortic balloon pump support. The secondary
outcomes included survival to the intended endpoint of bridge to transplantation/bridge to recovery, complica-
tions during subclavian artery–intra-aortic balloon pump support (eg, stroke, limb ischemia, brachial plexus in-
jury, dissection, bleeding requiring reoperation, and device-related infection), emergent surgery for worsening
heart failure, and ambulation during intra-aortic balloon pump support.
Results: The duration of balloon support ranged from 3 to 48 days (mean, 17.3  13.1 days). No patients died
during subclavian artery–intra-aortic balloon pump support. Of the 20 patients, 14 (70%) were successfully
bridged to transplant or left ventricular-assist device. Two patients (10%) required emergent left ventricular-
assist device for worsening heart failure.
Conclusions: An intra-aortic balloon pump inserted through the subclavian artery is a simple, minimally inva-
sive approach to mechanical support and is associated with limited morbidity and facilitates ambulation in pa-
tients with end-stage heart failure. (J Thorac Cardiovasc Surg 2012;144:951-5)E
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SThe intra-aortic balloon pump (IABP) was first used suc-
cessfully by Kantrowitz and colleagues1 in 1968 for patients
with cardiogenic shock. Annually, tens of thousands of pa-
tients benefit from the use of IABPs for indications includ-
ing refractory angina pectoris, post-cardiopulmonary
bypass shock, temporizing complications of percutaneous
coronary intervention, and complications of myocardial in-
farction refractory to pharmacologic therapy.2
Conventionally, IABPs are placed using femoral artery ac-
cess. However, this approach is associated with a number of
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The Journal of Thoracic and Carest—precluding ambulation. Second, there is a significant
risk of leg ischemia,with a reported incidenceof5% to 19%.2
Given these limitations, alternative approaches, includ-
ing by way of the subclavian artery (SCA), have been ex-
plored. Although technically more demanding and more
time consuming, the SCA approach overcomes important
limitations of femoral placement, because the SCA is gen-
erally free of atherosclerosis, even in patients with signifi-
cant peripheral arterial disease. Furthermore, it allows
patients to ambulate early. SCA placement of IABPs was
described by Mayer3 in 1978. McBride and colleagues4 de-
scribed ambulatory use of the balloon pump, and Cochran
and colleagues5 reported their ambulatory technique in 4
patients awaiting transplantation.
In the present series, we report a 3-year experience with
SCA-IABP at a single institution. This is the largest experi-
ence with SCA-IABPs published to date. The approach we
describe includes important technical modifications we
have developed during our growing experience.
METHODS
Data Collection
The present study was in accordance with the University of Chicago’s
institutional review board. The patient data, including preprocedurerdiovascular Surgery c Volume 144, Number 4 951
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
IABP ¼ intra-aortic balloon pump
LVAD ¼ left ventricular assist device
SCA ¼ subclavian artery
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Scharacteristics and outcomes, were obtained from our institutional cardiac
surgery outcomes database. Among the 20 patients receiving SCA-IABP
support, 15 (75%) were men and 5 (25%) were women. Their age ranged
from 20 to 70 years (mean, 57.8  13.0 years).
Study Population
The analysis included 20 consecutive patients who underwent SCA-
IABP principally to support heart failure while awaiting cardiac transplan-
tation. Other indications included deteriorating hemodynamics in patients
who were not transplant or ventricular assist device candidates and in 1 in-
stance with concomitant coronary artery bypass grafting (CABG) when it
was anticipated that the balloon might be necessary for an extended period.
Statistical Analysis
The patients were followed up from the date of SCA-IABP insertion to
the date of device removal, transplant, insertion of a ventricular assist
device, or death. The date of the last known follow-up examination was
September 28, 2011.
Operative Technique
In each instance, either the right (17 patients) or, less frequently, the left
SCA (3 patients)—when access through the right was not possible—was
isolated through a small incision in the infraclavicular region. After
5,000 U of heparin, a side-biting clamp was applied to the SCA. A 4 by
7-mm, tapered polytetrafluoroethylene graft (Gore-Tex, W. L. Gore & As-
sociates, Inc, Flagstaff, Ariz) was used. An incision was made 8 cm from
the most narrow portion and another 1.5 cm from the proximal end. This
was to ensure that the 1-way stopper slid over the distal portion and was
at the level of the skin without stretching or kinking. This was then anasto-
mosed to the artery using 6-0 polypropolene suture on a small needle. As
previously described,6 and as shown in Figure 1, the 1-way valve was ob-
tained from the 8F introducer sheath in our standardMaquet IABP catheter
kit (the sheath was cut at the hub, the side hole was cut off, the inner metal
coil was removed to prevent balloon rupture), and the 1-way valve was
placed on the graft and secured with three 2-0 silk ties. Under fluoroscopic
guidance, the glide wire was then inserted through the needle into the graft
and then through the SCA into the aorta.
Occasionally, the wire will pass directly into the descending aorta. On
other occasions, the wire will head preferentially into the ascending aorta.
The following procedure can be useful in redirecting the catheter:
1. Place a right coronary artery Amplatz catheter (AGA Medical, Ply-
mouth, Minn) in the ascending aorta and work the catheter leftward
and upward, toward the arch.
2. Use an Omniflush (AngioDynamics, Latham, NY) catheter (reverse an-
gle catheter) and non–stiff glide wire. Once the wire is pointed in the
appropriate direction, switch out the Omniflush for a glide catheter or
quick-cross catheter; and direct the wire into descending aorta.
3. If a type 1 or 2 arch is present and access is from the right, using a direc-
tional hydrophilic (eg, angled glide wire) and simple curved catheter
(eg, Kumpe [Cook, Bloomington, Ind] or Bernstein [AngioDynamics]),
advance the catheter into the arch and direct the catheter down the arch.
4. If a type 3 arch is present and access is from the right, a complex curved
catheter (eg, Simmons 1 [Cook]) can be advanced down the ascending
aorta and then pulled back to engage the tip on the greater curve.952 The Journal of Thoracic and Cardiovascular Surg5. As a last resort, the catheter can be placed in the left ventricle; then, us-
ing the inferior wall to support the catheter, a stiff wire can be inserted
upward back through the aortic valve into the ascending aorta. The wire
then typically goes into the arch and then into the descending aorta.
Next, the balloon is placed over the wire to a point 2 cm below the left
SCA. The distal end should be placed just distal to the left subclavian. This
can typically be confirmed by both transesophageal endocardiography and
fluoroscopy. The wound over the polytetrafluoroethylene graft (Gore-Tex,
W. L. Gore & Associates) is closed in layers. Therefore, the only foreign
material that traverses the skin is the balloon catheter, which does so
through a separate puncture site below the incision.
Outcomes
The primary outcome of interest was death during SCA-IABP support.
The secondary endpoints included survival to transplantation or recovery
without the need for additional mechanical support (eg, ventricular assist
device), interval to ambulation, stroke, bleeding requiring reoperation,
limb ischemia, other vascular complications, and device failure.
RESULTS
Study Population and Indications
The intent of the IABP was as a bridge to transplantation
in 17 patients, and 3 (patients 3, 9, and 17) had a non–bridge
to transplantation indication. The intent was to either
achieve recovery or temporize pending decisions about
more definitive therapy. One of these patients (patient 3)
was a 66-year-old patient who had undergone CABG and
repair of a postinfarct ventricular septal defect, who was re-
admitted with a leak from the ventricular septal defect patch
and sepsis. An IABP in the subclavian position was a bridge
to recovery because he was not a candidate for either a ven-
tricular assist device or transplantation because of the sep-
sis. A second patient (patient 9) was a 65-year-old man
who presented with cardiogenic shock after acute anterior
wall infarction. After percutaneous transluminal coronary
angioplasty, a femoral IABP and a tandem heart were
placed for support. A SCA-IABP was later placed for
long-term support in exchange for the femorally placed de-
vices. Because of a history of Alzheimer’s disease, he was
not a candidate for ventricular assist device or transplanta-
tion. The third patient (patient 17) was a 57-year-old man
with triple vessel disease and an ejection fraction of 15%.
He underwent subclavian IABP with concomitant CABG.
Patient Management
Of the 20 patients, 9 (45%) underwent the procedure un-
der local anesthesia and 11 (55%) required general anesthe-
sia. Of the 20 patients, 6 (30%) received no anticoagulation
or only prophylactic subcutaneous heparin doses postoper-
atively, and 14 (70%) received anticoagulation with intra-
venous heparin, low-molecular-weight heparin, or warfarin.
Primary Outcomes
As summarized in Table 1, the duration of balloon sup-
port ranged from 3 to 48 days (mean, 17.3  13.1 days).
No patients died during SCA-IABP support.ery c October 2012
FIGURE 1. A-E, Method used to obtain and secure the 1-way valve to the graft.
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Of the 17 patients who had undergone the procedure as
a bridge to transplantation, 14 (82.3%) eventually under-
went transplantation. Two patients (11.7%) required a ven-
tricular assist device for bridging. The first patient (patient
15) required an assist device 18 days after implantation
because of worsening heart failure. The second patient
(patient 8) required biventricular support 26 days after bal-
loon placement. In each case, the balloon was removed after
placement of these devices. A third patient (patient 19) was
awaiting transplantation 5 weeks after IABP implantation.
As summarized in Table 2, 3 cases of device failure oc-
curred. In 1 case, the middle of the balloon was not filling
through the proximal and distal ends. In 1 case, the balloonTABLE 1. Case studies of 20 patients who underwent SCA-IABP
insertion during a 3-year period
Pt.
no. Goal
Age
(y) Outcome
Interval from IABP
to outcome (d)
Duration of
IABP support (d)
1 BTT 62 TX 2 6
2 BTT 63 TX 1 7
3 Recovery 66 IABP out 24 24
4 BTT 58 TX 12 14
5 BTT 67 TX 13 16
6 BTT 56 TX 48 48
7 BTT 70 TX 1 3
8 BTT 20 BiVAD 26 26
9 Recovery 65 IABP out 9 9
10 BTT 65 TX 7 8
11 BTT 45 TX 6 8
12 BTT 61 TX 10 11
13 BTT 62 TX 43 44
14 BTT 29 TX 6 22
15 BTT 66 LVAD 18 19
16 BTT 57 TX 12 13
17 Recovery 57 IABP out 6 6
18 BTT 69 TX 2 4
19 BTT 50 Ongoing - 37
20 BTT 67 TX 19 20
SCA, Subclavian artery; IABP, intra-aortic balloon pump; Pt. no., patient number;
BTT, bridge to transplantation; TX, transplantation; BiVAD, biventricular assist
device.
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though the device appeared to be functioning properly, the
expected augmentation was suboptimal. Therefore, the de-
vice was exchanged, and augmentation improved.
Three patients (patients 3, 9, and 17) underwent the proce-
dure as a bridge to recovery for other indications. In all 3 pa-
tients, the balloon was able to be removed. Patient 17, who
had his device placed intraoperatively during high-risk
CABG, was successfully discharged. However, 2 patients
died several days (10 and 13 days) after removal of the bal-
loon pump; it had been determined that they were not candi-
dates for more long-term assistance or transplantation.
Except in the instances in which the patient was ventilator
dependent preoperatively, all patients were extubatedwithin
24 hours after the procedure. Fourteen patients (70%) were
able to ambulate within 1 to 5 days after insertion (mean,
2.6 1.2 days). Three (15%) of the remaining 6 underwent
transplantion within 2 days after IABP insertion; thus, the
IABP did not limit ambulation. The remaining 3 patients
(15%) did not ambulate—this was because they were ven-
tilator dependent or required multiple intravenous lines. No
patients developed bleeding requiring reoperation, device-
related infection, stroke, brachial plexus injury, ischemic
limb complications, or other vascular complications.
DISCUSSION
The support of patients with decompensating end-stage
heart failure remains a dilemma. Inotropic therapy is lim-
ited by the associated arrhythmias and potential for toler-
ance. Mechanical support using ventricular assist devices
is highly invasive, associated with significant adverse
events, and extremely costly. During the past 4 decades,
IABPs have compiled a long track record of successfully
supporting patients with decompensated heart failure. It
has a number of attractive characteristics. The cost is rela-
tively low. It can be inserted by the bedside, in the cardiac
catheterization laboratory, in the operating room, or in the
ward, if needed. IABPs are available in most countries
worldwide where interventional cardiology has achieved
some degree of sophistication.rdiovascular Surgery c Volume 144, Number 4 953
TABLE 2. Outcomes of 20 patients who underwent SCA-IABP
insertion during a 3-year period
Outcome of interest Patients (n)
Total patients 20 (100)
Death during IABP support 0 (0)
Primary endpoint 17 (85)
Device failure 3 (15)
Bleeding requiring reoperation 0 (0)
Device related infection 0 (0)
Brachial plexus injury 0 (0)
Stroke 0 (0)
Limb ischemia 0 (0)
Other vascular complications 0 (0)
Data in parentheses are percentages. SCA, Subclavian artery; IABP, intra-aortic bal-
loon pump.
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use of femoral access. First, IABPs with femoral insertion
require that the femoral and iliac arteries are free of signif-
icant obstructive disease. In addition, groin catheters pre-
vent ambulation. The patient is not allowed to bend that
hip, which also usually prevents the patient from sitting up-
right. Furthermore, despite the widespread use of sheathless
insertion of IABPs, there is a significant risk of ischemia to
the limb. Finally, femoral catheters can be associated with
greater infection rates7 than alternative access sites.
Alternative sites of IABP insertion have occasionally
been reported. The SCA approach was first proposed by
Mayer3 in 1978. He suggested subperiosteal wedge resec-
tion of the clavicle to gain access to the SCA. Only 1 clinical
report to date has mentioned the use of the SCA5 in any sus-
tained fashion. In that experience, 4 patients with significant
aortoiliac disease underwent IABP insertion through the
SCA approach jointly by cardiologists and vascular
surgeons.
Using the approach developed in the present series, SCA-
IABP is a relatively simple technique and offers another
tool in the mechanical support of patients with cardiogenic
shock. For transplant candidates, SCA-IABPs are particu-
larly useful in patients who have previously undergone car-
diac surgery, patients listed for multiorgan transplantation,
patients requiring repeat transplant, or patients with a con-
traindication to anticoagulation and are therefore candi-
dates for a ventricular assist device. The procedure can be
performed with the patient under local anesthesia. Further-
more, the use of the previously described 1-way valve
unique at our institution6 allows safe removal or exchange
at the bedside without vascular compromise to the arm. Ad-
ditional advantages of the SCA graft approach include no
special restrictions in terms of position in bed and the
opportunity to ambulate. This not allows only for more
freedom of movement, but also the possibility for the
deconditioned patient to participate in physical therapy
and rehabilitation.954 The Journal of Thoracic and Cardiovascular SurgWe have a large and increasing experience with implant-
able ventricular assist devices. However, the percentage of
these patients who had an indication of bridge to transplan-
tation was likely lower than at comparable centers. This
might be in part because increasingly we are using SCA-
IABP as a mechanical circulatory support for bridge to
transplantation. For example, from 2009 to 2010, we im-
planted 93 left ventricular assist devices (LVADs); 13
LVAD patients underwent transplantation; and 11 SCA-
IABP patients underwent transplantation. Furthermore,
we are developing more experience with SCA-IABP as
a bridge to recovery in patients with a low ejection fraction
with ischemic cardiomyopathy after standard cardiac sur-
gery procedures. This allows CABG and valve patients to
ambulate in the intensive care unit during their recovery af-
ter cardiac surgery. Anecdotally, they have lower inotrope
and vasoactive medication requirements. Finally, recently,
we have successfully used SCA-IABP to optimize
preventricular assist device patients before implantation.
In the present series, the largest described series to date,
no patients died during SCA-IABP support—although 2 pa-
tients required conversion to a LVAD. Furthermore, there
were no vascular complications, device-related infections,
strokes, or episodes of bleeding requiring reoperation. Im-
portantly, there were also no instances of bleeding from
the graft site from this technique. It is noteworthy that
most patients underwent transplantion within 2 weeks of
IABP insertion. This is in part because patients with IABPs
are generally high-priority candidates with a status 1A list-
ing. Also, unlike patients undergoing implantable ventricu-
lar assist devices, they do not require any significant
recovery time after implantation and before they are appro-
priate for transplantation.
Using the left SCA is generally less desirable because pa-
tients with end-stage heart failure often have automated im-
plantable cardioverter defibrillators in the left subclavian
vein. In 3 patients, the left subclavian was used because
the right was less desirable given the presence of an auto-
mated implantable cardioverter defibrillator in 1 case,
known left subclavian stenosis in 1 case, and a dialysis cath-
eter in 1 case. On 2 occasions, we have placed SCA-IABPS
on the same side as an automated implantable cardioverter
defibrillator without complications. Most of this experience
has described patients who were candidates for transplanta-
tion. However, in older patients with ectactic and athero-
sclerotic aortas, the left subclavian approach might be
preferable. Furthermore, additional imaging of the aorta
to assess for calcium might help risk stratify patients who
are at high risk of embolization and stroke.
We had 3 cases of device failure. In each case, the device
was exchanged over a wire without incident. Nevertheless,
the IABP does pose a risk to the patient; therefore, the func-
tion of the entire balloon should be confirmed under fluoros-
copy and by transesophageal echocardiography, ifery c October 2012
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changed by placing the glide wire through the balloon; re-
moving the balloon over the wire, being sure not to lose
the wire position; and then passing a new IABP over the
wire while stabilizing the 1-way valve between one’s fin-
gers. If this is difficult, it can be done under fluoroscopic
guidance. If necessary, the subclavicular incision might
need to be reopened in a sterile setting to achieve better con-
trol of the 1-way valve and balloon.
This SCAapproach has somedisadvantages. First, it is best
performed in the cardiac catheterization laboratory or the op-
erating room with radiologic screening and with a high-
quality image intensifier is available. Second, this approach
is more time-consuming than the femoral approach and,
therefore, is not recommended in an emergency setting in
which rapid initiation of support is needed. Finally, although
none were observed in this series, a number of potential seri-
ous complications can occur, including the risk of stroke—in
particular, because the balloon catheter traverses the arch of
the aorta—brachial plexus injury, and limb ischemia.
Implications
The patients described in the present cohort were largely
United Network for Organ Sharing status 1A patients. They
had significant morbidity; their expected survival in the ab-
sence of life-saving intervention could be measured in
weeks or even days; and we expected some undesirable out-
comes, regardless of management. Nevertheless, from our
experience, the SCA balloon pump offers an excellent
short-term solution in ambulatory patients with end-stage
heart failure, because it preserves mobility while awaiting
transplantation or recovery of myocardial function. We
did not observe any adverse events related to the placement
or use of the SCA-IABP, including stroke secondary to tra-
versing the arch, limb ischemia, bleeding events, thrombo-
embolic events, brachial plexus injuries, or device-related
infections. In some instances, the SCA-IABP was an ad-
junctive measure to support the hemodynamics while a con-
sensus could be reached and a decision made about the
suitability for a long-term solution. With increasing experi-
ence, we will better define the appropriate criteria for appli-
cation of this therapy. In particular, although in our series,
most patients required a bridge to transplantation, SCA-
IABPs might have a prophylactic role in the perioperative
period for high-risk cardiac surgery patients as a bridge to
recovery, particularly in patients with recent myocardial in-
farction, patients with ventricular septal defects, or patients
with a low ejection fraction and mitral valve regurgitation.
Study Limitations
The limitations of our study included all the caveats of
a small, nonrandomized, retrospective case series with
limited follow-up. Nevertheless, despite the lack ofThe Journal of Thoracic and Caa comparable technology (in terms of limited invasiveness
and cost) for ambulatory patients and given the generally
positive outcomes and low likelihood of a randomized
study of this approach, these data offer strong validation
of this method. However, additional follow-up is needed,
and future studies should include prospectively collected
data with standardized definitions for neurologic compli-
cations and other adverse events and the inclusion of eco-
nomic outcome measures such as patient satisfaction and
cost.
Hemodynamic information was not compiled. In our ex-
perience, analysis of hemodynamic data, particularly retro-
spective data, is often of limited value. These variables are
continuously changing over time and there is no standard
point when they are available for analysis. Furthermore,
with multiple classes of drugs, including vasopressors, ino-
tropes, and anesthetics, as well as multiple drugs within
each class, it is difficult to determine the effect of each rel-
ative to the device. Finally, analyzing multiple values over
time is a statistical challenge. Therefore, the present study
did not include hemodynamic data. The hemodynamic ben-
efits of IABP are well established, and no reason exists to
expect that this route of insertion would significantly alter
the effect of IABPs.
CONCLUSIONS
The SCA balloon pump can be placed safely, with mini-
mum morbidity in a high risk group of patients, often under
local anesthesia. It preserves ambulation when a patient is
ambulating preoperatively and allows an out of bed to chair
position in more debilitated patients, with obvious benefits
to pulmonary function. It is a reasonable option in deterio-
rating patients in heart failure who are on the transplant list
in the short term, up to several weeks. Additional studies are
needed to evaluate long-term outcomes, the necessity for
anticoagulation, and the cost/benefit ratio of this device
compared with alternatives, including LVADs.References
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